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Since their introduction into clinical practice, carbapenems
have been among the most powerful antibiotics for treating
serious infections caused by Gram-negative nosocomial
pathogens, including Enterobactericeae, Pseudomonas aeruginosa
and Acinetobacter baumannii [1]. Remarkable stability towards
most b-lactamases, including the extended-spectrum b-lacta-
mases (ESBLs), is one of the features accounting for the
unprecedented broad spectrum of activity exhibited by
carbapenems. Therefore, the emergence of b-lactamases
with carbapenem-hydrolyzing activity (carbapenemas-
es)—which can confer resistance to carbapenems in major
Gram-negative pathogens—is of major clinical concern. This
concern is further reinforced by the awareness that carba-
penems are the most effective agents for treatment of
serious infections caused by ESBL-producing Enterobacteria-
ceae [2,3], which are undergoing a massive increase both in
hospitals and in community settings [4].
Carbapenem resistance caused in strains of Gram-negative
pathogens by acquired carbapenemases has been reported
since the early 1990s [5,6]. However, its prevalence was
originally quite limited, with only sporadic cases or small out-
breaks being reported in Japan, caused by P. aeruginosa and
Enterobacteriaceae producing IMP-type metallo-b-lactamases
(MBLs) [7,8]. A progressive emergence of strains producing
different types of MBL has since been observed in several
countries from various continents, with an overall increasing
trend and some major nosocomial outbreaks [9,10]. How-
ever, the clinical impact of Gram-negative pathogens produc-
ing carbapenemases remained, overall, limited until the mid-
2000s; this is by no means comparable with the pandemic
dissemination of ESBL-producing Enterobacteriaceae observed
during the same period (especially after the emergence of
the CTX-M-type enzymes).
More recently, however, the ﬁeld of carbapenemase
research has experienced quite dramatic changes in terms of
enzyme diversity and epidemiological patterns. In fact, the
repertoire of acquired carbapenemases has become increas-
ingly complex, including not only several different types of
MBL (e. g. IMP, VIM, SPM, GIM, SIM, KHM, AIM, NDM and
DIM) and allelic variants thereof, but also various types of
class A (e.g. KPC, NMC/IMI and SME) and class D (e.g.
OXA-23, OXA-24, OXA-48 and OXA-58) serine carbapene-
mases [11–13]. Also, strains producing some of these
enzymes have spread at an alarming rate in some areas,
where they have attained a high level of endemicity.
The most paradigmatic examples of rapidly evolving dis-
semination of carbapenemase-producing strains are repre-
sented by Klebsiella pneumoniae strains producing KPC-type
serine carbapenemases or VIM-type metalloenzymes. The
KPC-producing klebsiellae have become a serious clinical
problem in several areas of North America, Israel and
Greece, and are now emerging in several additional countries
in Europe, Latin America and Asia [14]. In the New York
area, for instance, the dissemination of K. pneumoniae pro-
ducing KPC enzymes caused an impressive increase in carba-
penem resistance rates in this species (from 0.1% to 22%)
during the period 1999–2006 [15]. Similar rapid dissemina-
tion was observed in Israel, where KPC-producing K. pneu-
moniae strains were ﬁrst reported in 2004 [16] and
subsequently underwent substantial countrywide dissemina-
tion, with high rates in some institutions [17] (EARSS results
at http://www.rivm.nl/earss/result/). Some clones, such as the
one belonging to sequence type 258, have recently been
shown to play important roles in the spread of KPC-type
enzymes, even at the international and intercontinental levels
[18], thus emphasizing the importance of recognizing these
‘high-risk multidrug-resistant clones’ when tracing the molec-
ular epidemiology of antibiotic-resistant strains. On the other
hand, K. pneumoniae strains producing the VIM-1 MBL have
undergone massive dissemination in Greece since the mid-
2000s, and this is the main cause of the impressive increase
in carbapenem resistance rates among K. pneumoniae strains
isolated from that area, with values of non-susceptibility now
exceeding 40% [19] (EARSS results at http://www.rivm.nl/
earss/result/). Clonal expansion and plasmid-mediated hori-
zontal spread were found to underlie the rapid dissemination
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of VIM-1-producing klebsiellae [20], with implications for
infection control. Strains of K. pneumoniae and other entero-
bacterial species producing acquired carbapenemases (either
KPCs or MBLs) pose remarkable clinical challenges, not only
because they often exhibit an extended drug-resistant pheno-
type for all antibiotics except colistin and tigecycline, but also
because, for some of them, the conventional susceptibility
tests interpreted according to the current breakpoints may
show carbapenem MICs falling in the susceptible range,
although at higher than modal levels for strains of the
respective species [11]. The latter phenomenon has major
implications for the detection and surveillance of similar
strains, and raises the obvious question of whether carba-
penems can be effectively used for the treatment of serious
infections caused by carbapenemase-producing strains with
low MIC values.
Similar problems, although with an overall lower impact,
are caused by carbapenem-resistant A. baumannii strains pro-
ducing OXA-type carbapenemases, which often remain sus-
ceptible only to colistin and have undergone considerable
dissemination in some countries [21].
The increasing diversity of acquired carbapenemases, the
complex resistance phenotypes typical of these strains, and
the growing evidence that carbapenemase-producing strains
can rapidly disseminate and attain high prevalence rates has
deﬁnitively sanctioned the role of carbapenemases as antibi-
otic resistance determinants of the utmost clinical impor-
tance in Gram-negative bacterial pathogens. This has resulted
in a growing interest in carbapenemase-producing strains on
the part of the scientiﬁc community, which is evident from
the increase in the number of publications on this subject
appearing in the Medline database during recent years (38 in
2000–2002, 58 in 2003–2005, and 134 in 2006–2008, as
retrieved from the Medline database at http://www.ncbi.nlm.-
nih.gov/pubmed/, using the term ‘carbapenemase’ as query).
An increasing awareness of this problem prompted the
ESCMID Study Group for Antibiotic Resistance Suveillance
to convene, in late 2005, a meeting of experts to discuss the
current European perspective. The meeting, which was held
in Siena (Italy), was focused on MBLs, which, at that time,
appeared to be the major emerging problem in Europe. As a
follow-up to that meeting, the expert panel produced a dis-
cussion paper on the emerging problem of MBL producers,
in which several open issues were addressed in relation to
the detection, surveillance and control of these resistance
determinants and to the treatment of infections caused by
MBL producers [22]. Since then, the epidemiology of carba-
penemase producers has rapidly changed, resulting in major
clinical challenges such as the global emergence of KPC-pro-
ducing strains, the massive dissemination of VIM-producing
klebsiellae in some settings, and the diffusion of extended
drug-resistant clones of A. baumannii producing OXA-type
carbapenemases (see above). Thus, in late 2008, the ESCMID
Study Group for Antibiotic Resistance Suveillance recon-
vened a meeting of experts to discuss the most recent devel-
opments in the ﬁeld, with a broader perspective on Gram-
negatives producing acquired carbapenemases in general. At
that meeting, which was held in Athens (Greece), several
issues were discussed concerning the detection, surveillance
and control of these emerging resistance determinants, as
well as the treatment and outcome of infections caused by
carbapenemase-producing strains. As a follow-up to that
meeting, the expert panel has prepared two papers, which
are grouped as a theme section in this issue of Clinical Micro-
biology and Infection. The papers examine the major chal-
lenges posed by carbapenemase producers, and report some
consensus recommendations for dealing with speciﬁc aspects
concerning either the detection and surveillance of carbape-
nemase-producing Gram-negatives or infection control and
treatment strategies.
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